This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Antiplatelet drugs for secondary prevention of stroke

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Patients with stroke or TIA should receive two weeks of aspirin followed by definitive anti-platelet treatment (1):

  • clopidogrel is recommended as an option to prevent occlusive vascular events:
    • for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease or
    • for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated

  • modified-release dipyridamole in combination with aspirin is recommended as an option to prevent occlusive vascular events:
    • for people who have had a transient ischaemic attack or
    • for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated

  • modified-release dipyridamole alone is recommended as an option to prevent occlusive vascular events:
    • for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated or
    • for people who have had a transient ischaemic attack only if aspirin is contraindicated or not tolerated

People currently receiving clopidogrel or modified-release dipyridamole either with or without aspirin outside the criteria detailed above should have the option to continue treatment until they and their clinicians consider it appropriate to stop

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.